Biosimulation Market worth 2.88 Billion USD by 2022

1
(No Transcript)
2
Biosimulation Market is expected to reach
USD 2.88 Billion by 2022 from USD 1.38 Billion in
2017, at a CAGR of 15.9. The growth of this
market is majorly driven by factors such as the
increase in RD investments in the pharmaceutical
and biotechnology industries, growing adoption of
biosimulation software by regulatory bodies,
technologically advanced QSP systems, need to
curtail drug discovery and development costs, and
growth in the biologics and biosimilars markets.
3
The biosimulation market is expected to
reach USD 2.88 Billion by 2022 from USD 1.38
Billion in 2017, at a CAGR of 15.9.
4
Major Key Player Simulations Plus
(US) Physiomics (UK) Evidera (US) Schrödinger
(US) Dassault Systèmes (France) Rosa
(US) Nuventra Pharma (US)
5
North America to dominate the biosimulation
market In 2017, North America is expected to
dominate the market followed by Europe. The large
share of this geographical segment is attributed
to factors such as growth in the biotechnology
and pharmaceutical industry, a large number of
ongoing drug development processes, increased use
of personalized medicine, and increasing RD
expenditure by pharmaceutical and biotechnology
companies.